FDA approves cabozantinib in combination with nivolumab for first line treatment of advanced renal cell carcinoma

Approval based on results of CheckMate -9ER phase III trial which reported improved progression free survival (16.6 vs 8.3 months; HR 0.51; 95% CI: 0.41–0.64; P<0.0001) and 40% reduced mortality (HR: 0.60 [98.89% CI 0.40–0.89]; P=0.0010) of the combination vs sunitinib.

Biospace Inc.